Pfizer’s Paxlovid antiviral drug does not reduce risk of long Covid: Study
NEW YORK: US pharma giant Pfizer’s antiviral drug Paxlovid (Nirmatrelvir-ritonavir) does not reduce the risk of developing long Covid for vaccinated, non-hospitalised individuals, according to a study. A team of researchers from Univesity of California San Francisco (UCSF) revealed that among Paxlovid users, a higher proportion of individuals with acute symptoms rebound and test-positivity than previously …